Document:

ex103to8ka07358_10132008.htm

    Exhibit 10.3

     

    
      NEITHER
THIS WARRANT NOR THE WARRANT STOCK (AS HEREINAFTER DEFINED) HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS
OF ANY STATE.  THIS WARRANT AND THE WARRANT STOCK MAY BE TRANSFERRED
ONLY IN COMPLIANCE WITH THE ACT AND SUCH LAWS.  THIS LEGEND SHALL BE
ENDORSED UPON ANY WARRANT ISSUED IN EXCHANGE FOR THIS WARRANT.

      

      THIS
WARRANT IS SUBJECT TO THE TERMS OF THE CONVERTIBLE SECURED DEBENTURE PURCHASE
AGREEMENT, DATED AS OF OCTOBER 12, 2008 BETWEEN THE COMPANY AND THE HOLDER
HEREOF, A COPY OF WHICH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICES OF THE
COMPANY, AND ANY TRANSFERS AND TRANSFEREES OF THIS WARRANT AND THE WARRANT STOCK
ARE SUBJECT TO THE TERMS AND CONDITIONS OF SUCH AGREEMENT.

      

      

      Warrant
No. DB-__

      

      WARRANT

      For
the Purchase of Common Stock of

      HEALTH
SYSTEMS SOLUTIONS, INC.

      a
Nevada corporation

      

      VOID
AFTER 5:00 P.M., EASTERN STANDARD TIME, ON ____________, 2015.

      

      

      
        	
                _________
      Shares

              	
                October
      ____, 2008

              

      

      

      

      FOR VALUE RECEIVED, HEALTH SYSTEMS
SOLUTIONS, INC., a Nevada corporation (the “Company”), hereby
certifies that __________________________________ (the “Holder”) is
entitled, subject to the provisions of this Warrant, to purchase from the
Company up to ___________ shares of common stock (the “Common
Shares”), par
value $0.001 per share (“Common
Stock”), of the
Company at an exercise price per Common Share equal to [$4.00] [$2.00] [$.001]
per Common Share (the “Exercise
Price”), during
the period commencing October ___, 2008 and expiring at 5:00 P.M., Eastern
Standard time, on the seventh anniversary hereof.

      

      The
number of Common Shares to be received upon the exercise of this Warrant may be
adjusted from time to time as hereinafter set forth.  The Common
Shares deliverable upon such exercise, or the entitlement thereto upon such
exercise, and as adjusted from time to time, are hereinafter sometimes referred
to as “Warrant
Stock.”  The
Warrants issued on the same date hereof bearing the same terms and conditions as
this Warrant shall be collectively referred to as the “Warrants”.

       

      
        
          
          

        

        
          1

          
            

          

        

        
          
          

        

      

      

      The
Holder agrees with the Company that this Warrant is issued, and all the rights
hereunder shall be held subject to, all of the conditions, limitations and
provisions set forth herein.

      

      
        	
                 
      

              	
                1.

              	
                EXERCISE
      OF WARRANT

              

      

       

      (a)           By Payment of
Cash.  This Warrant may be exercised by its presentation and
surrender to the Company at its principal office (or such office or agency of
the Company as it may designate in writing to the Holder hereof), commencing on
___________, 2008 (“Date
of Issuance”) and
expiring at 5:00 P.M., Eastern Standard time, on the seventh anniversary of the
Date of Issuance, with the Warrant Exercise Form attached hereto duly executed
and accompanied by payment (either in cash or by certified or official bank
check or by wire transfer, payable to the order of the Company) of the Exercise
Price for the number of shares specified in such Form.

       

      The
Company agrees that the Holder hereof shall be deemed the record owner of such
Common Shares as of the close of business on the date on which this Warrant
shall have been presented and payment made for such Common Shares as aforesaid
whether or not the Company or its transfer agent is open for
business.  Certificates for the Common Shares so purchased shall be
delivered to the Holder hereof within a reasonable time, not exceeding 15 days,
after the rights represented by this Warrant shall have been so
exercised.  If this Warrant should be exercised in part only, the
Company shall, upon surrender of this Warrant for cancellation, execute and
deliver a new Warrant evidencing the rights of the Holder hereof to purchase the
balance of the shares purchasable hereunder as soon as reasonably
possible.

      

      (b)           Cashless
Exercise.  In lieu of the payment method set forth in Section
1(a) above, the Holder may elect to exchange all or some of this Warrant for the
Common Shares equal to the value of the amount of this Warrant being exchanged
on the date of exchange.  If the Holder elects to exchange this
Warrant as provided in this Section 1(b), the Holder shall tender to the Company
this Warrant for the amount being exchanged, along with written notice of the
Holder’s election to exchange some or all of this Warrant, and the Company shall
issue to the Holder the number of Common Shares computed using the following
formula:

       

       

      
        
          
            
              	
                      X  =
       Y
      (A-B)  

                    
	 
      	
                             
      A

                    

            

          

        

        

        
          
            
              	 
      	
                      Where:

                    	
                      X
      =

                    	
                      The
      number of Common Shares to be issued to the Holder.

                    
	 
      	 
      	 
      	 
      
	 
      	 
      	
                      Y
      =

                    	
                      The
      number of Common Shares purchasable under the amount of this Warrant being
      exchanged (as adjusted to the date of such
calculation).

                    
	 
      	 
      	 
      	 
      
	 
      	 
      	
                      A
      =

                    	
                      The
      Market Price of one Common Share.

                    
	 
      	 
      	 
      	 
      
	 
      	 
      	
                      B
      =

                    	
                      The
      Exercise Price (as adjusted to the date of such
    calculation).

                    

            

          

        

      

       

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      The
Warrant exchange shall take place on the date specified in the notice or if the
date the notice is received by the Company is later than the date specified in
the notice, on the date the notice is received by the Company.

      

      As used
herein in the phrase “Market
Price” at any
date shall be deemed to be the last reported sale price or the closing price of
the Common Stock on any exchange (including the National Association of
Securities Dealers Automated Quotation System (“Nasdaq”)) on
which the Common Stock is listed or the closing price as quoted on the OTC
Bulletin Board, whichever is applicable, or, in the case no such reported sale
takes place on such day, the average of the last reported sales prices or
quotations for the last five trading days, in either case as officially reported
or quoted by the principal securities exchange or the OTC Bulletin Board, and if
the Common Stock is not listed or quoted as determined in good faith by
resolution of the Board of Directors of the Company, based on the best
information available to it.

      

      (c)           “Easy Sale”
Exercise.  In lieu of the payment method set forth in Section
1(a) above, when permitted by law and applicable regulations (including rules of
Nasdaq and the Financial Industry Regulatory Authority, successor to the
National Association of Securities Dealers (“FINRA”)), the
Holder may pay the aggregate Exercise Price (the “Exercise
Amount”) through
a “same day sale” commitment from the Holder (and if applicable a broker-dealer
that is a member of FINRA (a “FINRA
Dealer”)),
whereby the Holder irrevocably elects to exercise this Warrant and to sell a
portion of the shares so purchased to pay the Exercise Amount and the Holder
(or, if applicable, the FINRA Dealer) commits upon sale (or, in the case of the
FINRA Dealer, upon receipt) of such shares to forward the Exercise Amount
directly to the Company.

       

      2.           COVENANTS
BY THE COMPANY

       

      The
Company covenants and agrees as follows:

       

      (a)           Reservation of
Shares.  During the period within which the rights represented
by this Warrant may be exercised, the Company shall, at all times, reserve and
keep available out of its authorized capital stock, solely for the purposes of
issuance upon exercise of this Warrant, such number of its Common Shares as
shall be issuable upon the exercise of this Warrant.  If at any time
the number of authorized Common Shares shall not be sufficient to effect the
exercise of this Warrant, the Company will take such corporate action as may be
necessary to increase its authorized but unissued Common Shares to such number
of shares as shall be sufficient for such purpose.  The Company shall
have analogous obligations with respect to any other securities or property
issuable upon exercise of this Warrant.

       

      (b)           Valid Issuance,
etc.  All Common Shares which may be issued upon exercise of
the rights represented by this Warrant included herein will be, upon payment
thereof, validly issued, fully paid, non-assessable and free from all taxes,
liens and charges with respect to the issuance thereof.

       

      (c)           Taxes.  All original
issue taxes payable in respect of the issuance of Common Shares upon the
exercise of the rights represented by this Warrant shall be borne by the
Company, but in no event shall the Company be responsible or liable for income
taxes or transfer taxes upon the issuance or transfer of this Warrant or the
Warrant Stock.

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

       

      (d)           Fractional
Shares.  The Company shall not be required to issue
certificates representing fractions of Common Shares.  In lieu of any
fractional interests, the Company shall make a cash payment equal to the
Exercise Price multiplied by such fraction.

       

      3.           EXCHANGE
OR ASSIGNMENT OF WARRANT

       

      This
Warrant is exchangeable, without expense, at the option of the Holder, upon
presentation and surrender hereof to the Company for other Warrants of different
denominations, entitling the Holder to purchase in the aggregate the same number
of Common Shares purchasable hereunder.  Subject to the provisions of
this Warrant and the receipt by the Company of any required representations and
agreements, upon surrender of this Warrant to the Company with the Warrant
Assignment Form annexed hereto duly executed and funds sufficient to pay any
transfer tax, the Company shall, without additional charge, execute and deliver
a new Warrant in the name of the assignee named in such instrument of assignment
and this Warrant shall promptly be canceled.  In the event of a
partial assignment of this Warrant, the new Warrants issued to the assignee and
the Holder shall make reference to the aggregate number of shares of Warrant
Stock issuable upon exercise of this Warrant.

       

      4.           RIGHTS
OF THE HOLDER

       

      The
Holder shall not, by virtue hereof, be entitled to any voting or other rights of
a stockholder of the Company, either at law or in equity, and the rights of the
Holder are limited to those expressed in this Warrant.

       

      5.           ADJUSTMENT
OF EXERCISE PRICE

       

      (a)           Common Stock Dividends; Common Stock
Splits; Reclassification.  If the Company, at any time while
this Warrant is outstanding, (a) shall pay a stock dividend on its Common Stock,
(b) subdivide outstanding shares of Common Stock into a larger number of shares
(or combine the outstanding shares of Common Stock into a smaller number of
shares) or (c) issue by reclassification of shares of Common Stock any shares of
capital stock of the Company, then (i) the Exercise Price shall be multiplied by
a fraction, the numerator of which shall be the number of shares of Common Stock
outstanding prior to such event and the denominator of which shall be the number
of shares of Common Stock outstanding after such event and (ii) the number of
shares of the Warrant Stock shall be multiplied by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately
after such event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately prior to such event.  Any
adjustment made pursuant to this Section 5.1 shall become effective immediately
after the record date for the determination of stockholders entitled to receive
such dividend or distribution or, in the case of a subdivision or
re-classification, shall become effective immediately after the effective date
thereof.

       

      (b)           Rights; Options; Warrants or Other
Securities.  If the Company, at any time while this Warrant is
outstanding, shall fix a record date for the issuance of rights, options,
warrants or other securities to all the holders of its Common Stock entitling
them to subscribe for or purchase, convert to, exchange for or otherwise acquire
shares of Common Stock for no consideration or at a price per share less than
the Exercise Price, the Exercise Price shall be multiplied by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issuance or sale plus the number of shares of Common
Stock which the aggregate consideration received by the Company would purchase
at the Exercise Price, and the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to  such issuance
date plus the number of additional shares of Common Stock offered for
subscription, purchase, conversion, exchange or acquisition, as the case may
be.  Such adjustment shall be made whenever such rights, options,
warrants or other securities are issued, and shall become effective immediately
after the record date for the determination of stockholders entitled to receive
such rights, options, warrants or other securities.

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

       

      (c)           Subscription
Rights.  If the Company, at any time while this Warrant is
outstanding, shall fix a record date for the distribution to holders of its
Common Stock, evidence of its indebtedness or assets or rights, options,
warrants or other security entitling them to subscribe for or purchase, convert
to, exchange for or otherwise acquire any security (excluding those referred to
in Sections 5(a) and 5(b) above), then in each such case the Exercise Price at
which this Warrant shall thereafter be exercisable shall be determined by
multiplying the Exercise Price in effect immediately prior to such record date
by a fraction, the numerator of which shall be the per-share Market Price on
such record date less the then fair market value at such record date of the
portion of such assets or evidence of indebtedness so distributed applicable to
one outstanding share of Common Stock as determined by the Board of Directors in
good faith, and the denominator of which shall be the Exercise Price as of such
record date; provided, however, that in the event of a distribution exceeding
10% of the net assets of the Company, such fair market value shall be determined
by an appraiser selected in good faith by the registered owners of a majority of
the Warrant Stock then outstanding; and provided, further, that the Company,
after receipt of the determination by such appraiser shall have the right to
select in good faith an additional appraiser meeting the same qualifications, in
which case the fair market value shall be equal to the average of the
determinations by each such appraiser.  Such adjustment shall be made
whenever any such distribution is made and shall become effective immediately
after the record date mentioned above.

       

      (d)           Rounding.  All
calculations under this Section 5 shall be made to the nearest cent or the
nearest l/l00th of a share, as the case may be.

       

      (e)           Notice of
Adjustment.  Whenever the Exercise Price is adjusted pursuant
to this Section 5, the Company shall promptly deliver to the Holder a notice
setting forth the Exercise Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment.  Such notice shall
be signed by the chairman, president or chief financial officer of the
Company.

       

      (f)           Treasury
Shares.  The number of shares of Common Stock outstanding at
any given time shall not include shares owned or held by or for the account of
the Company, and the disposition of any shares so owned or held shall be
considered an issue or sale of Common Stock by the Company.

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      (g)           Change of Control; Compulsory Share
Exchange.  In case of (A) any Change of Control Transaction (as
defined below) or  (B) any compulsory share exchange pursuant to which
the Common Stock is converted into other securities, cash or property (each, an
“Event”),
lawful provision shall be made so that the Holder shall have the right
thereafter to exercise this Warrant for shares of stock and other securities,
cash and property receivable upon or deemed to be held by holders of Common
Stock following such Event, and the Holder shall be entitled upon such Event to
receive such amount of shares of stock and other securities, cash or property as
the shares of the Common Stock of the Company into which this Warrant could have
been exercised immediately prior to such Event (without taking into account any
limitations or restrictions on the exercisability of this Warrant) would have
been entitled; provided, however, that in the case of a transaction specified in
(A), above, in which holders of the Company’s Common Stock receive cash, the
Holder shall have the right to exercise the Warrant for such number of shares of
the surviving company equal to the amount of cash into which this Warrant is
then exercisable, divided by the fair market value of the shares of the
surviving company on the effective date of such Event.  The terms of
any such Event shall include such terms so as to continue to give to the Holder
the right to receive the securities, cash or property set forth in this Section
5(g) upon any exercise or redemption following such Event, and, in the case of
an Event specified in (A), above, the successor corporation or other entity (if
other than the Company) resulting from such reorganization, merger or
consolidation, or the person acquiring the properties and assets, or such other
controlling corporation or entity as may be appropriate, shall expressly assume
the obligation to deliver the securities or other assets which the Holder is
entitled to receive hereunder.  The provisions of this Section 5(g)
shall similarly apply to successive Events. “Change
of Control Transaction” means
the occurrence of any (i) merger or consolidation of the Company with or into
another entity, unless the holders of the Company’s securities immediately prior
to such transaction or series of transactions continue to hold at least 50% of
such securities following such transaction or series of transactions, (ii) a
sale, conveyance, lease, transfer or disposition of all or substantially all of
the assets of the Company in one or a series of related transactions or (iii)
the execution by the Company of an agreement to which the Company is a party or
by which it is bound, providing for any of the events set forth above in (i) or
(ii).

       

      (h)           Issuances Below Exercise
Price.  If the Company, at any time while this Warrant is
outstanding:

       

      (i)           issues
or sells, or is deemed to have issued or sold, any Common Stock;

       

      (ii)         in
any manner grants, issues or sells any rights, options, warrants, options to
subscribe for or to purchase Common Stock or any stock or other securities
convertible into or exchangeable for Common Stock (other than any Excluded
Securities (as defined below)) (such rights, options or warrants being herein
called “Options” and such
convertible or exchangeable stock or securities being herein called “Convertible
Securities”);
or

       

      (iii)         in
any manner issues or sells any Convertible Securities;

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

       

      for (a)
with respect to paragraph (i) above, a price per share, or (b) with respect to
paragraphs (ii) or (iii) above, a price per share for which Common Stock
issuable upon the exercise of such Options or upon conversion or exchange of
such Convertible Securities is, less than the Exercise Price in effect
immediately prior to such issuance or sale, then, immediately after such
issuance, sale or grant, the Exercise Price shall be reduced to a price equal to
the price per share of the Common Stock sold or the exercise price or conversion
price of the Options and Convertible Securities, as applicable.  No
modification of the issuance terms shall be made upon the actual issuance of
such Common Stock upon conversion or exchange of such Options or Convertible
Securities. The number of Common Shares issuable upon exercise of this
Warrant  shall be increased to an amount equal to the quotient of (A)
the product of (x) the Exercise Price in effect immediately prior to the
adjustment multiplied by (y) the number of Common Shares issuable upon exercise
of this Warrant immediately prior to the adjustment, divided by (B) the adjusted
Exercise Price.  If there is a change at any time in (i) the exercise
price provided for in any Options, (ii) the additional consideration, if any,
payable upon the issuance, conversion or exchange of any Convertible Securities
or (iii) the rate at which any Convertible Securities are convertible into or
exchangeable for Common Stock, then immediately after such change the Exercise
Price shall be adjusted to Exercise Price which would have been in effect at
such time had such Options or Convertible Securities still outstanding provided
for such changed exercise price, additional consideration or changed conversion
rate, as the case may be, at the time initially granted, issued or sold;
provided that no adjustment shall be made if such adjustment would result in an
increase of the Exercise Price then in effect.

      

      “Excluded
Securities” means (i) options to be granted pursuant to a stock option
plan approved by Stanford International Bank Ltd. (“Stanford”); (ii)
shares of Common Stock issued upon conversion or exercise of warrants, options
or other securities convertible into Common Stock which have been specifically
disclosed to Stanford in the Convertible Secured Debenture Purchase Agreement
dated as of October 12, 2008 between the Company and Stanford, or (iii) shares
of Common Stock or securities convertible into or exercisable for shares of
Common Stock issued or deemed to be issued by the Company in connection with a
strategic acquisition by the Company of the assets or business, or division
thereof, of another entity which acquisition has been approved by Stanford in
writing.

      

      (i)           Effect on Exercise Price of Certain
Events.  For purposes of determining the adjusted Exercise
Price under Section 5(h), the following shall be applicable:

       

      (i)           Calculation of Consideration
Received.  If any Common Stock, Options or Convertible
Securities are issued or sold or deemed to have been issued or sold for cash,
the consideration received therefor will be deemed to be the net amount received
by the Company therefor, without deducting any expenses paid or incurred by the
Company or any commissions or compensations paid or concessions or discounts
allowed to underwriters, dealers or others performing similar services in
connection with such issue or sale.  In case any Common Stock, Options
or Convertible Securities are issued or sold for a consideration other than
cash, the amount of the consideration other than cash received by the Company
will be the fair value of such consideration, except where such consideration
consists of securities listed or quoted on a national securities exchange or
national quotation system, in which case the amount of consideration received by
the Company will be the arithmetic average of the closing sale price of such
security for the five (5) consecutive trading days immediately preceding the
date of receipt thereof.  In case any Common Stock, Options or
Convertible Securities are issued to the owners of the non-surviving entity in
connection with any merger in which the Company is the surviving entity, the
amount of consideration therefor will be deemed to be the fair value of such
portion of the net assets and business of the non-surviving entity as is
attributable to such Common Stock, Options or Convertible Securities, as the
case may be.  The fair value of any consideration other than cash or
securities will be determined jointly by the Company and the registered owners
of a majority of the Warrant Stock then outstanding.  If such parties
are unable to reach agreement within 10 days after the occurrence of an event
requiring valuation (the “Valuation
Event”), the
fair value of such consideration will be determined within 48 hours of the 10th
day following the Valuation Event by an appraiser selected in good faith by the
Company and agreed upon in good faith by the registered owners of a majority of
the Warrant Stock then outstanding.  The determination of such
appraiser shall be binding upon all parties absent manifest error.

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

       

      (ii)          Integrated
Transactions.  In case any Option is issued in connection with
the issue or sale of other securities of the Company, together comprising one
integrated transaction in which no specific consideration is allocated to such
Options by the parties thereto, the Options will be deemed to have been issued
for an aggregate consideration of $.001.

       

      (iii)         Record Date.  If
the Company takes a record of the holders of Common Stock for the purpose of
entitling them (a) to receive a dividend or other distribution payable in Common
Stock, Options or in Convertible Securities or (b) to subscribe for or purchase
Common Stock, Options or Convertible Securities, then such record date will be
deemed to be the date of the issue or sale of the shares of Common Stock deemed
to have been issued or sold upon the declaration of such dividend or the making
of such other distribution or the date of the granting of such right of
subscription or purchase, as the case may be.

       

      (iv)        Other Events.  If
any event occurs that would adversely affect the rights of the Holder of this
Warrant but is not expressly provided for by this Section 5 (including, without
limitation, the granting of stock appreciation rights, phantom stock rights or
other rights with equity features), then the Company’s Board of Directors will
make an appropriate adjustment in the Exercise Price so as to protect the rights
of the Holder; provided, however, that no such adjustment will increase the
Exercise Price.

       

      (j)           Notice of Certain
Events.  If:

       

      (i)           the
Company shall declare a dividend (or any other distribution) on its Common
Stock;

       

      (ii)          the
Company shall declare a special nonrecurring cash dividend on or a redemption of
its Common Stock;

       

      (iii)         the
Company shall authorize the granting to the holders of all of its Common Stock
rights or warrants to subscribe for or purchase any shares of capital stock of
any class or of any rights;

       

      (iv)        the
approval of any stockholders of the Company shall be required in connection with
any capital reorganization, reclassification of the Company’s capital stock, any
consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or
property; or

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      (v)         the
Company shall authorize the voluntary or involuntary dissolution, liquidation or
winding up of the affairs of the Company;

       

      then the
Company shall cause to be filed at each office or agency maintained for the
purpose of exercise of this Warrant, and shall cause to be delivered to the
Holder, at least 30 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (provided such notice shall not include any
material non-public information) stating (a) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of
Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (b) the date on which
such reorganization, reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of
which it is expected that holders of Common Stock of record shall be entitled to
exchange their shares of Common Stock for securities, cash or other property
deliverable upon such reorganization, reclassification, consolidation, merger,
sale, transfer or share exchange; provided, however, that the failure to mail
such notice or any defect therein or in the mailing thereof shall not affect the
validity of the corporate action required to be specified in such
notice.  Nothing herein shall prohibit the Holder from exercising this
Warrant during the 30-day period commencing on the date of such
notice.

      

      (k)           Increase in Exercise
Price.  In no event shall any provision in this Section 5 cause
the Exercise Price to be greater than the Exercise Price on the date of issuance
of this Warrant, except for a combination of the outstanding shares of Common
Stock into a smaller number of shares as referenced in Section 5(a)
above.

       

      6.           RESTRICTIONS
ON EXERCISE

       

      (a)           Investment
Intent.  Unless, prior to the exercise of the Warrant, the
issuance of the Warrant Stock has been registered with the Securities and
Exchange Commission pursuant to the Act, the Warrant Exercise Form shall be
accompanied by a representation of the Holder to the Company to the effect that
such shares are being acquired for investment and not with a view to the
distribution thereof, and such other representations and documentation as may be
required by the Company, unless in the opinion of counsel to the Company such
representations or other documentation are not necessary to comply with the
Act.

       

      7.           RESTRICTIONS
ON TRANSFER

       

      (a)           Transfer to Comply with the
Securities Act of 1933.  Neither this Warrant nor any Warrant
Stock may be sold, assigned, transferred or otherwise disposed of except as
follows:  (1) to a person who, in the opinion of counsel satisfactory
to the Company, is a person to whom this Warrant or the Warrant Stock may
legally be transferred without registration and without the delivery of a
current prospectus under the Act with respect thereto and then only against
receipt of an agreement of such person to comply with the provisions of this
Section 7 with respect to any resale, assignment, transfer or other disposition
of such securities; (2) to any person upon delivery of a prospectus then meeting
the requirements of the Act relating to such securities and the offering thereof
for such sale, assignment, transfer or disposition; or (3) to any “affiliate”
(as such term is used in Rule 144 promulgated pursuant to the Act) of the
Holder.

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

       

      (b)           Legend.  Subject to
the terms hereof, upon exercise of this Warrant and the issuance of the Warrant
Stock, all certificates representing such Warrant Stock shall bear on the face
or reverse thereof substantially the following legend:

       

      “The
securities which are represented by this certificate have not been registered
under the Securities Act of 1933, and may not be sold, transferred, hypothecated
or otherwise disposed of until a registration statement with respect thereto is
declared effective under such act, or the Company receives an opinion of counsel
for the Company that an exemption from the registration requirements of such act
is available.”

      

      8.           LOST,
STOLEN OR DESTROYED WARRANTS

       

      In the
event that the Holder notifies the Company that this Warrant has been lost,
stolen or destroyed and provides (a) a letter, in form reasonably satisfactory
to the Company, to the effect that it will indemnify the Company from any loss
incurred by it in connection therewith, and/or (b) an indemnity bond in such
amount as is reasonably required by the Company, the Company having the option
of electing either (a) or (b) or both, the Company may, in its sole discretion,
accept such letter and/or indemnity bond in lieu of the surrender of this
Warrant as required by Section 1 hereof.

       

      9.           SUBSEQUENT
HOLDERS

       

      Every
Holder hereof, by accepting the same, agrees with any subsequent Holder hereof
and with the Company that this Warrant and all rights hereunder are issued and
shall be held subject to all of the terms, conditions, limitations and
provisions set forth in this Warrant, and further agrees that the Company and
its transfer agent, if any, may deem and treat the registered holder of this
Warrant as the absolute owner hereof for all purposes and shall not be affected
by any notice to the contrary.

       

      10.         NOTICES

       

      Any
notice required or permitted hereunder shall be given in writing (unless
otherwise specified herein) and shall be effective upon personal delivery, via
facsimile (upon receipt of confirmation of error-free transmission and mailing a
copy of such confirmation, postage prepaid by certified mail, return receipt
requested) or two business days following deposit of such notice with an
internationally recognized courier service, with postage prepaid and addressed
the other party at the following address, or at such other addresses as a party
may designate by five days advance written notice to the other party
hereto.

       

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

      

      
         

        
          
            
              
                
                  
                    
                      	Company: 	Health Systems
      Solutions Group, LLC 

                              489
      Fifth Avenue, 3rd Floor

                              New
      York, N.Y. 10017

                              Facsimile
      No.:  (212) 214-0348

                              Attn:
      Chief Financial Officer

                            
	 	 
	 	
                              And

                            
	 	 
	 	
                              Health
      Systems Solutions Group, LLC

                              489
      Fifth Avenue, 3rd Floor

                              New
      York, N.Y. 10017

                              Facsimile
      No.: (212) 214-0348

                              Attn:
      General Counsel

                            
	 	 
	 	
                              Except
      after November 1, 2008, to those persons at:

                              

                              Health
      Systems Solutions Group, LLC

                              42
      W. 39th Street, 6th Floor

                              New
      York, N.Y. 10018

                              Facsimile
      No.: (212) 214-0348

                            
	 	 
	 	
                              With
      a copy to (which will not constitute notice):

                              

                              Olshan
      Grundman Frome Rosenzweig &

                              Wolosky
      LLP

                              Park
      Avenue Tower

                              65
      East 55th Street

                              New
      York, NY 10022-1106

                              Facsimile
      No.: (212) 451-2222

                              Attn:  Steve
      Wolosky

                            
	 	 
	with a copy
      to:   	
                              Carlton
      Fields P.A.

                              4000
      International Place

                              100
      SE 2nd Street

                              Miami,
      FL 33131

                              Attention:
      Seth P. Joseph

                              Facsimile:
      305-530-0055

                            
	 	 
	Holder: 	
                              Stanford
      International Bank Ltd.

                              No.
      11 Pavilion Drive

                              St.
      John’s

                              Antigua,
      West Indies

                              Attention:
      James M. Davis, Chief Financial Officer

                              Facsimile:
      901-680-5265

                            

                    

                  

                

              

            

          

        

         

      

       

      
         

        
          
            
            

          

          
            11

            
              

            

          

          
            
            

          

        

        
 

      

      11.         
GOVERNING
LAW; JURISDICTION

       

      This
Warrant shall be governed by and interpreted in accordance with the laws of the
State of Florida, without regard to its principles of conflict of
laws.  Any action or proceeding seeking to enforce any provision of,
or based on any right arising out of, this Warrant may be brought against any
party in the federal courts of Florida or the state courts of the State of
Florida, and each of the parties consents to the jurisdiction of such courts and
hereby waives, to the maximum extent permitted by law, any objection, including
any objections based on forum non conveniens, to the bringing of any such
proceeding in such jurisdictions.

       

      

      (Signature
on the following page)

       

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

      

      

      IN WITNESS WHEREOF, the
Company has caused this Warrant to be signed on its behalf, in its corporate
name, by its duly authorized officer, all as of the day and year first above
written.

       

      
        
          
            	
                    HEALTH
      SYSTEMS SOLUTIONS, INC.

                  
	 
      
	 
      
	 
      
	
                    By:

                  	 
      
	
                    Name:

                  	 
      
	
                    Title:

                  	 
      

          

        

      

      

                                                 

      
        
          
          

        

        
          13ex104to8ka07358_10132008.htm

    Exhibit 10.4

     

    
      

      

      

      

      

      

      

      

      

      

      VOTING
AGREEMENT

      

       

      BY
AND AMONG

      

       

      HEALTH
SYSTEMS SOLUTIONS, INC.,

      

       

      HSS
ACQUISITION CORP.

      

       

      AND

      

       

      [STOCKHOLDER]

       

      

       

      DATED
AS OF OCTOBER 13, 2008

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      

      

      INDEX OF
DEFINED TERMS

       

      
        
          
            	 
      	
                    Page

                  
	 
      	 
      
	
                    Agreement

                  	
                    1

                  
	
                    Beneficial
      Ownership

                  	
                    1

                  
	
                    Beneficially
      Own

                  	
                    2

                  
	
                    Beneficially
      Owned

                  	
                    2

                  
	
                    Common
      Stock

                  	
                    2

                  
	
                    Company

                  	
                    1

                  
	
                    Covered
      Shares

                  	
                    2

                  
	
                    Encumbrance

                  	
                    2

                  
	
                    Existing
      Shares

                  	
                    1

                  
	
                    Grantees

                  	
                    3

                  
	
                    Merger

                  	
                    1

                  
	
                    Merger
      Agreement

                  	
                    1

                  
	
                    Merger
      Sub

                  	
                    1

                  
	
                    Parent

                  	
                    1

                  
	
                    Section
      2.1 Matters

                  	
                    3

                  
	
                    Stockholder

                  	
                    1

                  
	
                    Transfer

                  	
                    2

                  

          

        

      

       

      
 

      
        
          
          

        

        
          i

          
            

          

        

        
          
          

        

      

      

      VOTING
AGREEMENT, dated as of October 13, 2008 (this “Agreement”), by and
among Health Systems Solutions, Inc., a Nevada corporation (“Parent”), HSS
Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent
(“Merger Sub”),
and [___________] (the “Stockholder”).

       

      W
I T N E S S E T H:

       

      WHEREAS,
concurrently with the execution of this Agreement, Parent, Merger Sub and
Emageon, Inc., a Delaware corporation (the “Company”) are
entering into an Agreement and Plan of Merger, dated as of the date hereof (as
amended, supplemented, restated or otherwise modified from time to time, the
“Merger
Agreement”) pursuant to which, among other things, Merger Sub will merge
with and into the Company (the “Merger”) and each
outstanding share of Common Stock will be converted into the right to receive
the merger consideration specified therein.

       

      WHEREAS,
as of the date hereof, the Stockholder owns beneficially and of record the
number of shares of Common Stock set forth opposite Stockholder’s name on
Schedule I hereto (the “Existing
Shares”).

       

      WHEREAS,
as a material inducement to Parent entering into the Merger Agreement, Parent
has required that the Stockholder agree, and the Stockholder has agreed, to
enter into this Agreement and abide by the covenants and obligations with
respect to the Covered Shares (as hereinafter defined) set forth herein and in
executing and delivering the Merger Agreement, Parent and Merger Sub are relying
on the agreements contained herein.

       

      NOW
THEREFORE, in consideration of the foregoing and the mutual representations,
warranties, covenants and agreements herein contained and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, and intending to be legally bound hereby, the parties hereto agree
as follows:

       

      ARTICLE
I

       

      GENERAL

       

      1.1.           Defined
Terms.  The following capitalized terms, as used in this
Agreement, shall have the meanings set forth below.  Capitalized terms
used but not otherwise defined herein shall have the meanings ascribed thereto
in the Merger Agreement.

       

      “Beneficial
Ownership” by a Person of any securities includes ownership by any Person who,
directly or indirectly, through any contract, arrangement, understanding,
relationship or otherwise, has or shares (i) voting power which includes
the power to vote, or to direct the voting of, such security; and/or
(ii) investment power which includes the power to dispose, or to direct the
disposition, of such security; and shall otherwise be interpreted in accordance
with the term “beneficial ownership” as defined in Rule 13d-3 adopted by the
Securities and Exchange Commission under the Securities Exchange Act of 1934, as
amended; provided that for purposes of determining Beneficial Ownership, a
Person shall be deemed to be the Beneficial Owner of any securities which such
Person has, at any time during the term of this Agreement, the right to acquire
pursuant to any agreement, arrangement or understanding or upon the exercise of
conversion rights, exchange rights, warrants or options, or otherwise
(irrespective of whether the right to acquire such securities is exercisable
immediately or only after the passage of time, including the passage of time in
excess of 60 days, the satisfaction of any conditions, the occurrence of any
event or any combination of the foregoing).  The terms “Beneficially Own” and
“Beneficially
Owned” shall have a correlative meaning.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      “Common
Stock” means the common stock, par value $0.001 per share, of the
Company.

       

      “Covered
Shares” means, with respect to the Stockholder, the Stockholder’s Existing
Shares, together with any shares of Common Stock or other voting capital stock
of the Company and any securities convertible into or exercisable or
exchangeable for shares of Common Stock or other voting capital stock of the
Company, in each case, that the Stockholder acquires Beneficial Ownership of on
or after the date hereof.

       

      “Encumbrance”
means any security interest, pledge, mortgage, lien (statutory or other),
charge, option to purchase, lease or other right to acquire any interest or any
claim, restriction, covenant, title defect, hypothecation, assignment, deposit
arrangement or other encumbrance of any kind or any preference, priority or
other security agreement or preferential arrangement of any kind or nature
whatsoever (including any conditional sale or other title retention
agreement.

       

      “Transfer”
means, directly or indirectly, to sell, transfer, assign, pledge, encumber,
hypothecate or similarly dispose of (by merger (including by conversion into
securities or other consideration), by tendering into any tender or exchange
offer, by operation of law or otherwise), either voluntarily or involuntarily,
or to enter into any contract, option or other arrangement or understanding with
respect to the voting of or sale, transfer, assignment, pledge, encumbrance,
hypothecation or similar disposition of (by merger, by tendering into any tender
or exchange offer, by operation of law or otherwise).

       

      ARTICLE
II

       

      VOTING

       

      2.1.           Agreement to
Vote.  The Stockholder hereby irrevocably and unconditionally
agrees that during the time this Agreement is in effect, at the Company
Stockholders Meeting and at any other meeting of the stockholders of the
Company, however called, including any adjournment or postponement thereof, or
in any other circumstance in which the vote, consent or approval of stockholders
of the Company, in their capacity as stockholders, is sought with respect to the
Merger Agreement or any Takeover Proposal, the Stockholder shall, in each case,
to the fullest extent that such matters are submitted for the vote, written
consent or approval of the Stockholder and the Stockholder is entitled to vote
thereon or consent thereto: (a) appear at each such meeting or otherwise cause
the Covered Shares to be counted as present thereat for purposes of calculating
a quorum; and (b) vote in favor of (or cause to be voted in favor of), in person
or by proxy, deliver (or cause to be delivered) a written consent or otherwise
approve on behalf of all of the Covered Shares (i) the adoption of the Merger
Agreement and any related proposal in furtherance thereof, as reasonably
requested by Parent, submitted for the vote, written consent or approval of the
Company’s stockholders; (ii) against any action, proposal or agreement submitted
for the vote, written consent or approval of the Company’s stockholders that is
in opposition to, or to the Stockholder’s knowledge (based upon the advice of
counsel) is competitive or materially inconsistent with, the Merger or to the
Stockholder’s knowledge (based upon the advice of counsel) would result in a
breach of any covenant, representation or warranty or any other obligation or
agreement of the Company contained in the Merger Agreement, or of the
Stockholder contained in this Agreement; and (iii) against any Takeover Proposal
and against any other action, agreement or transaction submitted for the vote,
written consent or approval of stockholders that the Stockholder knows would
impede, interfere with, delay, postpone, discourage, frustrate the purposes of
or adversely affect the Merger or the other transactions contemplated by the
Merger Agreement or this Agreement or the performance by the Company of its
obligations under the Merger Agreement or by the Stockholder of its obligations
under this Agreement.

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      2.2.           No Inconsistent
Agreements.  The Stockholder hereby covenants and agrees that,
except for this Agreement, and except as may be permitted by Section 4.3(b)
hereof, it (a) has not entered into, and shall not enter into at any time while
this Agreement remains in effect, any voting agreement or voting trust with
respect to the Covered Shares with respect to any of the matters described in
Section 2.1 (the “Section 2.1 Matters”)
or, except with Parent or Merger Sub, any contract, option or other agreement or
binding understanding with respect to any Transfer of any or all of the Covered
Shares, (b) has not granted, and shall not grant at any time while this
Agreement remains in effect (except pursuant to Section 2.3), a proxy, consent
or power of attorney with respect to the Covered Shares with respect to any of
the Section 2.1 Matters and (c) has not knowingly taken and shall not knowingly
take any action that would make any representation or warranty of the
Stockholder contained herein untrue or incorrect or have the effect of
preventing or disabling the Stockholder from performing any of its obligations
under this Agreement.

       

      2.3.           Proxy.  Without
in any way limiting the Stockholder’s right to vote the Covered Shares in its
sole discretion on any matters other than the Section 2.1 Matters that may be
submitted to a stockholder vote, consent or other approval, the Stockholder
hereby irrevocably appoints as its proxy and attorney-in-fact, Stan Vashovsky
and Michael Levine, pursuant to a proxy to be delivered to Parent substantially
in the form attached hereto as Annex A, in their respective capacities as
officers of Parent, and any individual who shall hereafter succeed to any such
officer of Parent, and any other Person designated in writing by Parent
(collectively, the “Grantees”), each of them individually, with full power of
substitution, to vote or execute written consents with respect to the Covered
Shares and, in the discretion of the Grantees, with respect to any proposed
postponements or adjournments of any annual or special meeting of the
stockholders of the Company at which any of the Section 2.1 Matters is or was to
be considered.  This proxy is coupled with an interest and shall be
irrevocable until the termination of this Agreement in accordance with its
terms, in which event this proxy shall automatically be revoked without any
further action by any party.  The Stockholder will take such further
action or execute such other instruments as may be necessary to effectuate the
intent of this proxy and hereby revokes any proxy previously granted by it with
respect to the Covered Shares with respect to any of the Section 2.1
Matters.  So long as the proxy granted under this Section 2.3 is a
valid uncontested proxy that is effective to deliver the votes of the Covered
Shares, the Stockholder shall be deemed to be fulfilling its obligations under
Section 2.1.  If Parent believes that such proxy is not a valid proxy
or if Parent otherwise does not wish to utilize the proxy, Parent will
immediately so notify the Stockholder in writing so that the Stockholder will be
able to perform its obligations under Section 2.1.

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

       

      ARTICLE
III

       

      REPRESENTATIONS
AND WARRANTIES

       

      3.1.           Representations and
Warranties of the Stockholder.  The Stockholder hereby
represents and warrants to Parent and Merger Sub as follows:

       

      (a)           Organization;
Authorization; Validity of Agreement; Necessary Action.  The
Stockholder has full power and authority to execute and deliver this Agreement,
to perform its obligations hereunder and to consummate the transactions
contemplated hereby.  This Agreement has been duly executed and
delivered by the Stockholder and, assuming this Agreement constitutes a valid
and binding obligation of the other parties hereto, constitutes a legal, valid
and binding obligation of the Stockholder, enforceable against it in accordance
with its terms, subject to bankruptcy, insolvency, fraudulent transfer,
moratorium, reorganization or similar laws affecting the rights of creditors
generally and the availability of equitable remedies (regardless of whether such
enforceability is considered in a proceeding in equity or at law).

       

      (b)           Ownership.  As
of the date hereof, the Stockholder’s Existing Shares are, and all of the
Covered Shares will be, Beneficially Owned including owned of record by the
Stockholder.  The Stockholder has good and marketable title to the
Stockholder’s Existing Shares, free and clear of any Encumbrances.  As
of the date hereof, the Stockholder’s Existing Shares constitute all of the
shares of Common Stock Beneficially Owned or owned of record by the
Stockholder.  Except for the rights granted to Parent hereby, the
Stockholder has and will have at all times through the Closing Date sole voting
power (including the right to control such vote as contemplated herein) with
respect to the Section 2.1 Matters, sole power of disposition, sole power to
issue instructions with respect to the Section 2.1 Matters, and sole power to
agree to all of the matters set forth in this Agreement, in each case, with
respect to all of the Stockholder’s Existing Shares and Covered
Shares.

       

      (c)           No
Violation.  The execution, delivery and performance of this Agreement
by the Stockholder does not and will not (whether with or without notice or
lapse of time, or both) (i) violate, conflict with or result in the breach of
any of the terms or conditions of, result in any (or the right to make any)
modification of or the cancellation or loss of a benefit under, require any
notice, consent or action under, or otherwise give any Person the right to
terminate, accelerate obligations under or receive payment or additional rights
under, or constitute a default under, any Contract to which the Stockholder is a
party or by which it is bound or (ii) violate any Law applicable to the
Stockholder or by which any of the Stockholder’s assets or properties is bound,
except for any of the foregoing as would not, either individually or in the
aggregate, impair the ability of the Stockholder to perform its obligations
hereunder or to consummate the transactions contemplated hereby on a timely
basis.

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

       

      ARTICLE
IV

       

      OTHER
COVENANTS

       

      4.1.           Prohibition on Transfers,
Other Actions.  Except as permitted by Section 4.3(b), the
Stockholder hereby agrees not to (i) Transfer any of the Covered Shares,
Beneficial Ownership thereof or any other interest specifically therein, except
to participate in the Merger; (ii) enter into any agreement, arrangement or
understanding with any Person (other than Parent or Merger Sub), or knowingly
(based upon advice of counsel) take any other action, that violates or conflicts
with the Stockholder’s representations, warranties, covenants and obligations
under this Agreement; or (iii) take any action that could restrict or otherwise
affect the Stockholder’s legal power, authority and right to comply with and
perform its covenants and obligations under this Agreement.  Any
Transfer in violation of this provision shall be void.

       

      4.2.           Stock Dividends,
etc.  In the event of a stock split, stock dividend or
distribution, or any change in the Common Stock by reason of any split-up,
reverse stock split, recapitalization, combination, reclassification, exchange
of shares or the like, the terms “Existing Shares” and “Covered Shares” shall be
deemed to refer to and include such shares as well as all such stock dividends
and distributions and any securities into which or for which any or all of such
shares may be changed or exchanged or which are received in such
transaction.

       

      4.3.           No
Solicitation.

       

      (a)           The
Stockholder hereby agrees that during the term of this Agreement, except as
permitted by Section 4.3(b), it shall not, and shall use its reasonable best
efforts to ensure that any of its Affiliates or Representatives do not, directly
or indirectly, (i) initiate, solicit, publicly propose or encourage the
submission of a Takeover Proposal, (ii) participate or engage in negotiations
with respect to any Takeover Proposal or (iii) furnish any non-public
information regarding the Company or the Merger to any other Person; provided, however, that nothing
in this Section 4.3(a) shall prevent the Stockholder, in the Stockholder’s
capacity as a director or executive officer of the Company, from engaging in any
activity permitted pursuant to Section 5.3 of the Merger Agreement, and no
action by the Company or any of its Affiliates in compliance with Section 5.3 of
the Merger Agreement shall be a violation by Stockholder of this Section
4.3.

       

      (b)           Notwithstanding
anything in this Agreement to the contrary, in the event the Company Board (or
the Strategic Alternatives Committee) exercises its rights under Section 5.3 of
the Merger Agreement to (i) furnish information with respect to the Company and
its Subsidiaries to any Person, and (ii) participate, engage or assist in any
manner in discussions or negotiations with any Person, in each case, in
compliance with Section 5.3 of the Merger Agreement, then (x) the Stockholder
may likewise furnish any such information to such Person and participate, engage
or assist in any manner in such discussions or negotiations with such Person,
provided, that
any action taken by the Stockholder shall be taken only in coordination with the
Company Board (or the Strategic Alternatives Committee), and (y) in connection
with the Company’s termination of the Merger Agreement pursuant to Section
5.3(d) of the Merger Agreement in order to enter into a transaction which
constitutes a Superior Proposal, Stockholder shall be entitled to enter into a
voting or other support agreement with the Person making the Superior Proposal,
provided, that
the effectiveness of such agreement shall be conditioned upon the termination of
the Merger Agreement in compliance with the Article VII thereof.

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      4.4.           Waiver of Appraisal
Rights.  The Stockholder agrees not to exercise any rights of
appraisal or any dissenters’ rights that the Stockholder may have (whether under
applicable Law or otherwise) or could potentially have or acquire in connection
with the Merger.

       

      4.5.           Further
Assurances.  From time to time, at Parent’s request and without
further consideration, the Stockholder shall execute and deliver such additional
documents and take all such further action as may be reasonably necessary to
effect the actions and consummate the transactions contemplated by this
Agreement.

       

      ARTICLE
V

       

      MISCELLANEOUS

       

      5.1.           Termination.  This
Agreement shall remain in effect until the earliest to occur of (i) the
Closing Date, (ii) the termination of the Merger Agreement in accordance with
its terms; provided, however, that the
provisions of the Article V shall survive any termination of this Agreement;
(iii) six months after the date hereof; or (iv) at the Stockholder’s option,
upon written notice by the Stockholder to the Parent from and after any material
amendment, waiver or modification to the terms of the Merger Agreement or any
amendment, waiver or modification to the terms of the Merger Agreement that
changes the form of or decreases the amount of payment from what is set forth in
the Merger Agreement of, the Merger Consideration.  Nothing in this
Section 5.1 and no termination of this Agreement shall relieve or otherwise
limit any party of liability for willful breach of this Agreement.

       

      5.2.           No Ownership
Interest.  Nothing contained in this Agreement shall be deemed
to vest in Parent or Merger Sub any direct or indirect ownership or incidence of
ownership of or with respect to any Covered Shares, except as otherwise provided
herein.  All rights, ownership and economic benefits of and relating
to the Covered Shares shall remain vested in and belong to the Stockholder, and
neither Parent nor Merger Sub shall have any authority to direct the Stockholder
in the voting or disposition of any of the Covered Shares, except as otherwise
provided herein.

       

      5.3.           Notices.

       

      (a)           All
notices and other communications hereunder shall be in writing and shall be
deemed given when delivered personally, by facsimile (upon telephonic
confirmation of receipt), on the first business day following the date of
dispatch if delivered by a recognized next day courier service or on the third
business day following the date of mailing if delivered by registered or
certified mail, return receipt requested, post prepaid.  All notices
hereunder shall be delivered as set forth below, or pursuant to such other
instructions as may be designated in writing in accordance with this Section 5.3
by the party to receive such notice.

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

       

      
        	
                 
      

              	
                (i)

              	
                If
      to Parent or Merger Sub, to:

              

      

       

      Health
Systems Solutions Group, LLC

      489 Fifth
Avenue, 3rd Floor

      New York,
N.Y. 10017

      Facsimile
No.: (212) 214-0348

      Attn:
Chief Financial Officer

       

      and

       

      Health
Systems Solutions Group, LLC

      489 Fifth
Avenue, 3rd Floor

      New York,
N.Y. 10017

      Facsimile
No.: (212) 214-0348

      Attn:
General Counsel

       

      Except
after November 1, 2008, to those persons at:

       

      Health
Systems Solutions Group, LLC

      42 W.
39th Street, 6th Floor

      New York,
N.Y. 10018

      Facsimile
No.: (212) 214-0348

       

      With a
copy to (which will not constitute notice to Parent or Merger Sub):

       

      Olshan
Grundman Frome Rosenzweig & Wolosky LLP

      Park
Avenue Tower

      65 East
55th Street

      New York,
NY 10022-1106

      Facsimile
No.: (212) 451-2222

      Attn:
Steve Wolosky

       

      
        	
                 
      

              	
                (ii)

              	
                if
      to the Stockholder, to the address set forth on Schedule I
      hereto.

              

      

       

      5.4.           Interpretation.  The
words “hereof,” “herein” and “hereunder” and words of similar import when used
in this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement, and Section references are to this
Agreement unless otherwise specified.  Whenever the words “include,”
“includes” or “including” are used in this Agreement, they shall be deemed to be
followed by the words “without limitation.”  The meanings given to
terms defined herein shall be equally applicable to both the singular and plural
forms of such terms.  The table of contents and headings contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.  This Agreement is
the product of negotiation by the parties having the assistance of counsel and
other advisers.  It is the intention of the parties that this
Agreement not be construed more strictly with regard to one party than with
regard to the others.

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

       

      5.5.           Counterparts.  This
Agreement may be executed by facsimile and in counterparts, all of which shall
be considered one and the same agreement and shall become effective when
counterparts have been signed by each of the parties and delivered to the other
parties, it being understood that all parties need not sign the same
counterpart.

       

      5.6.           Entire
Agreement.  This Agreement, together with the agreements and
other documents and instruments referred to herein or annexed hereto, embody the
complete agreement and understanding among the parties hereto with respect to
the subject matter hereof and supersede and preempt any prior understandings,
agreements or representations by or among the parties, written and oral, that
may have related to the subject matter hereof in any way.

       

      5.7.           Governing Law; Waiver of
Jury Trial.

       

      (a)           This
Agreement, and all claims or causes of action (whether at law, in contract or in
tort) that may be based upon, arise out of or relate to this Agreement or the
negotiation, execution or performance hereof, shall be governed by and construed
in accordance with the Laws of the State of Delaware, without giving effect to
any choice or conflict of Law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of the Laws
of any jurisdiction other than the State of Delaware.

       

      (b)           Each
party hereto hereby waives, to the fullest extent permitted by applicable law,
any right it may have to a trial by jury in respect of any Action arising out of
or relating to this Agreement.  Each party hereto (i) certifies that
no representative, agent or attorney of any other party has represented,
expressly or otherwise, that such party would not, in the event of any action,
seek to enforce the foregoing waiver and (ii) acknowledges that it and the other
parties hereto have been induced to enter into this Agreement, by, among other
things, the mutual waiver and certifications in this Section 5.7.

       

      5.8.           Amendment;
Waiver.  This Agreement may not be amended except by an
instrument in writing signed by each of the parties hereto.  Each
party may waive any right of such party hereunder by an instrument in writing
signed by such party and delivered to Parent and the Stockholder.

       

      5.9.           Remedies.  All
rights, powers and remedies provided under this Agreement or otherwise available
in respect hereof at law or in equity shall be cumulative and not alternative,
and the exercise or beginning of the exercise of any thereof by any party shall
not preclude the simultaneous or later exercise of any other such right, power
or remedy by such party.

       

      5.10.         Severability.  Any
term or provision of this Agreement which is determined by a court of competent
jurisdiction to be invalid or unenforceable in any jurisdiction shall, as to
that jurisdiction, be ineffective to the extent of such invalidity or
unenforceability without rendering invalid or unenforceable the remaining terms
and provisions of this Agreement or affecting the validity or enforceability of
any of the terms or provisions of this Agreement in any other jurisdiction, and
if any provision of this Agreement is determined to be so broad as to be
unenforceable, the provision shall be interpreted to be only so broad as is
enforceable, in all cases so long as neither the economic nor legal substance of
the transactions contemplated hereby is affected in any manner adverse to any
party or its stockholders or partners, as applicable.  Upon any such
determination, the parties shall negotiate in good faith in an effort to agree
upon a suitable and equitable substitute provision to effect the original intent
of the parties as closely as possible and to the end that the transactions
contemplated hereby shall be fulfilled to the maximum extent
possible.

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      5.11.         Successors and Assigns;
Third Party Beneficiaries.  Neither this Agreement nor any of
the rights or obligations of any party under this Agreement shall be assigned,
in whole or in part (by operation of law or otherwise), by any party without the
prior written consent of the other parties hereto.  Subject to the
foregoing, this Agreement shall bind and inure to the benefit of and be
enforceable by the parties hereto and their respective successors and permitted
assigns.  Nothing in this Agreement, express or implied, is intended
to confer on any Person other than the parties hereto or their respective
successors and permitted assigns any rights, remedies, obligations or
liabilities under or by reason of this Agreement.

       

      5.12.         Stockholder
Capacity.  The restrictions and covenants of the Stockholder
hereunder shall not be binding, and shall have no effect, in any way with
respect to any director or officer of the Company or any of its Subsidiaries in
such Person’s capacity as such a director or officer, nor shall any action taken
by any such director or officer in his or her capacity as such be deemed a
breach by the Stockholder of this Agreement.

       

      

       

      [Remainder
of this page intentionally left blank]

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

       

      IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed
(where applicable, by their respective officers or other authorized Person
thereunto duly authorized) as of the date first written above.

       

      
        
          	 
      	
                  PARENT:

                
	 
      	 
      
	 
      	
                  HEALTH
      SYSTEMS SOLUTIONS, INC.

                
	 
      	 
      
	 
      	 
      
	 
      	
                  By:

                	
                  
                     

                  

                
	 
      	
                  Name:

                	
                  Michael
      G. Levine

                
	 
      	
                  Title:

                	
                  Chief
      Financial Officer

                

        

        

        

        
          	 
      	
                  MERGER
      SUB:

                
	 
      	 
      
	 
      	
                  HSS
      ACQUISITION CORP.

                
	 
      	 
      
	 
      	 
      
	 
      	
                  By:

                	
                  
                     

                  

                
	 
      	
                  Name:

                	
                  Michael
      G. Levine

                
	 
      	
                  Title:

                	
                  Chief
      Executive Officer

                

        

        

        

        
          	 
      	
                  [STOCKHOLDER]

                
	 
      	 
      
	 
      	 
      
	 
      	
                  By:

                	 
      
	 
      	
                  Name:

                	 
      
	 
      	
                  Title:

                	 
      

        

      

       

       

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

       

      ANNEX A

       

      IRREVOCABLE
PROXY

       

      Dated as
of _______, 2008

       

      The
undersigned Stockholder (the “Stockholder”) of
Emageon, Inc., a Delaware corporation (the “Company”), hereby
irrevocably (to the fullest extent permitted by law) appoints each of Stan
Vashovsky and Michael Levine, as the sole and exclusive attorneys and proxies of
the undersigned, with full power of substitution and resubstitution, for and in
the name, place and stead of the Stockholder, to vote and exercise all voting
and related rights (to the full extent that the undersigned is entitled to do
so) with respect to all of the shares of capital stock of the Company that now
are or hereafter may be beneficially owned by the undersigned, and any and all
other shares or securities of the Company issued or issuable in respect thereof
on or after the date hereof (collectively, the “Covered Shares”), in
accordance with the terms of this Proxy.  The Covered Shares
beneficially owned by the Stockholder as of the date of this Proxy are listed on
Schedule I to this Proxy.  Upon the Stockholder’s execution of this
Proxy, any and all prior proxies given by the undersigned with respect to any
Covered Shares are hereby revoked and terminated, and the Stockholder agrees not
to grant any subsequent proxies with respect to the Covered Shares, with respect
to any of the matters referred to in any of clauses (a) through (c) below until
after the Expiration Time (as defined below).

       

      This
Proxy is irrevocable (to the fullest extent permitted by law), is coupled with
an interest and is granted pursuant to that certain Voting Agreement of even
date herewith (the “Voting Agreement”) by
and among Health Systems Solutions, Inc., a Nevada corporation (“Parent”), HSS
Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent
(“Merger Sub”), and the undersigned Stockholder, and is granted in consideration
of Parent entering into that certain Agreement and Plan of Merger of even date
herewith (as it may hereafter be amended from time to time in accordance with
the provisions thereof, the “Merger Agreement”) by
and among Parent, Merger Sub and the Company.  The Merger Agreement
provides that Merger Sub will merge with and into the Company (the “Merger”) and the
Stockholder will be entitled to receive the merger consideration specified
therein.  The term “Expiration Time”, as
used in this Proxy, shall mean the earliest to occur of the events specified in
Section 5.1 of the Voting Agreement.

       

      The
attorneys and proxies named above, and each of them, are hereby authorized and
empowered by the Stockholder, at any time prior to the Expiration Time, to act
as the Stockholder’s attorney and proxy to vote all of the Covered Shares, and
to exercise all voting, consent and similar rights of the undersigned with
respect to all of the Covered Shares (including, without limitation, the power
to execute and deliver written consents) at every annual or special meeting of
stockholders of the Company (and at every adjournment or postponement thereof),
and in every written consent in lieu of such meeting:

       

      (a)  in
favor of the adoption of the Merger Agreement and any related proposal in
furtherance thereof, as reasonably requested by Parent, submitted for the vote,
written consent or approval of the Company’s stockholders;

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      (b)  against
any action, proposal or agreement submitted for the vote, written consent or
approval of the Company’s stockholders that is in opposition to, or to the
Stockholder’s knowledge (based upon the advice of counsel) is competitive or
materially inconsistent with, the Merger or to the Stockholder’s knowledge
(based upon the advice of counsel) would result in a breach of any covenant,
representation or warranty or any other obligation or agreement of the Company
contained in the Merger Agreement, or of the Stockholder contained in the Voting
Agreement; and

       

      (c)  against
any Takeover Proposal and against any other action, agreement or transaction
submitted for the vote, written consent or approval of stockholders that the
Stockholder knows would impede, interfere with, delay, postpone, discourage,
frustrate the purposes of or adversely affect the Merger or the other
transactions contemplated by the Merger Agreement or the Voting Agreement or the
performance by the Company of its obligations under the Merger Agreement or by
the Stockholder of its obligations under the Voting Agreement.

       

      Any term
or provision of this Proxy that is invalid or unenforceable in any situation in
any jurisdiction shall not affect the validity or enforceability of the
remaining terms and provisions hereof or the validity or enforceability of the
offending term or provision in any other situation or in any other
jurisdiction.  If the final judgment of a court of competent
jurisdiction declares that any term or provision hereof is invalid or
unenforceable, the Stockholder agrees that the court making such determination
shall have the power to limit the term or provision, to delete specific words or
phrases, or to replace any invalid or unenforceable term or provision with a
term or provision that is valid and enforceable and that comes closest to
expressing the intention of the invalid or unenforceable term or provision, and
this Proxy shall be enforceable as so modified.  In the event such
court does not exercise the power granted to it in the prior sentence, the
Stockholder agrees to replace such invalid or unenforceable term or provision
with a valid and enforceable term or provision that will achieve, to the extent
possible, the economic, business and other purposes of such invalid or
unenforceable term.

       

      The
restrictions and covenants of the Stockholder hereunder shall not be binding,
and shall have no effect, in any way with respect to any director or officer of
the Company or any of its Subsidiaries in such Person’s capacity as such a
director or officer, nor shall any action taken by any such director or officer
in his or her capacity as such be deemed a breach by the Stockholder of this
Proxy.

       

      Any
obligation of the Stockholder hereunder shall be binding upon the successors and
assigns of the Stockholder.

       

      This
Proxy shall terminate, and be of no further force and effect, automatically upon
the Expiration Time.

       

      [signature
page follows]

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      COUNTERPART
SIGNATURE PAGE

       

      IN
WITNESS WHEREOF, the Stockholder has caused this Irrevocable Proxy to be duly
executed as of the day and year first above written.

       

      
        	 
      	
                [STOCKHOLDER]

              
	 
      	 
      
	 
      	 
      
	 
      	
                By:

              	 
      
	 
      	 
      	
                Name:

              	 
      
	 
      	 
      	
                Title:

              	 
      

      

      

      

      with a
copy to:

       

      Health
Systems Solutions Group, LLC

      489 Fifth
Avenue, 3rd Floor

      New York,
N.Y. 10017

      Facsimile
No.: (212) 214-0348

      Attn:
Chief Financial Officer

       

      and

       

      Health
Systems Solutions Group, LLC

      489 Fifth
Avenue, 3rd Floor

      New York,
N.Y. 10017

      Facsimile
No.: (212) 214-0348

      Attn:
General Counsel

       

      Except
after November 1, 2008, to those persons at:

       

      Health
Systems Solutions Group, LLC

      42 W.
39th Street, 6th Floor

      New York,
N.Y. 10018

      Facsimile
No.: (212) 214-0348

       

      With a
copy to (which will not constitute notice to Parent or Merger Sub):

       

      Olshan
Grundman Frome Rosenzweig & Wolosky LLP

      Park
Avenue Tower

      65 East
55th Street

      New York,
NY 10022-1106

      Facsimile
No.: (212) 451-2222

      Attn:
Steve Wolosky

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]